National Center for Biotechnology Information

The National Center for Biotechnology Information (NCBI) serves as an international resource for the scientific research community - providing access to public databases and software tools for analyzing biological data, as well as performing research in computational biology. The NCBI was established in 1988 by an act of the United States Congress as division of the National Library of Medicine at the National Institutes of Health, with a mission to find new approaches to deal with the increasing volume and complexity of biological data in order to facilitate the understanding of genes and their role in health and disease.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

GEOVAX ANNOUNCES $10 MILLION PRIVATE PLACEMENT

GeoVax, Inc. | January 15, 2022

news image

GeoVax Labs, Inc. a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock ...

Read More

SEVERITY OF COVID-19 MAY DEPEND ON YOUR INDIVIDUAL GENETIC VARIATION IN IMMUNE SYSTEM

SciTechDaily | April 19, 2020

news image

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte...

Read More

MEDICAL

BAKAR LABS AND THE CYSTIC FIBROSIS FOUNDATION SUPPORT ENTREPRENEURS TO DEVELOP NEW GENETIC THERAPIES FOR CF

Bakar Labs | April 19, 2022

news image

Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis. The CF Foundation is sponsoring a "Golden Ticket" competition at the new incubator and is encouraging companies with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may work in CF to apply. Applications open M...

Read More

OUTSOURCING BIOLOGY CRO AND PRECLINICAL RESEARCH STUDIES DURING COVID19 PANDEMIC

PR Newswire | May 15, 2020

news image

While the COVID-19 pandemic continues to evolve, many Cancer Research Institutions and Pharma/Biotech companies are considering how to restart the biomedical research and drug development programs. This may include thinking through meeting the timeline, risk of mitigation actions, and possible program reprioritizations as components of the strategy to return to normal operations. Our preclinical services allow scientists to discover new innovative therapies effective in serious diseases without ...

Read More
news image

INDUSTRIAL IMPACT

GEOVAX ANNOUNCES $10 MILLION PRIVATE PLACEMENT

GeoVax, Inc. | January 15, 2022

GeoVax Labs, Inc. a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock ...

Read More
news image

SEVERITY OF COVID-19 MAY DEPEND ON YOUR INDIVIDUAL GENETIC VARIATION IN IMMUNE SYSTEM

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte...

Read More
news image

MEDICAL

BAKAR LABS AND THE CYSTIC FIBROSIS FOUNDATION SUPPORT ENTREPRENEURS TO DEVELOP NEW GENETIC THERAPIES FOR CF

Bakar Labs | April 19, 2022

Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis. The CF Foundation is sponsoring a "Golden Ticket" competition at the new incubator and is encouraging companies with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may work in CF to apply. Applications open M...

Read More
news image

OUTSOURCING BIOLOGY CRO AND PRECLINICAL RESEARCH STUDIES DURING COVID19 PANDEMIC

PR Newswire | May 15, 2020

While the COVID-19 pandemic continues to evolve, many Cancer Research Institutions and Pharma/Biotech companies are considering how to restart the biomedical research and drug development programs. This may include thinking through meeting the timeline, risk of mitigation actions, and possible program reprioritizations as components of the strategy to return to normal operations. Our preclinical services allow scientists to discover new innovative therapies effective in serious diseases without ...

Read More